Related Experiment Videos
Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism
Insights
Spironolactone treatment for essential hypertension altered blood electrolytes but showed limited efficacy in normalizing blood pressure for most patients. Its mechanism in hypertension remains unclear, suggesting mineralocorticoid excess is not the primary cause.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Essential hypertension is a common condition with complex pathophysiology.
- Mineralocorticoid excess is a potential, though often undiagnosed, cause of hypertension.
- Spironolactone is a mineralocorticoid receptor antagonist used in managing hypertension and heart failure.
Purpose of the Study:
- To investigate the effects of high-dose spironolactone on essential hypertension.
- To explore the relationship between spironolactone's biochemical effects and its clinical efficacy.
- To assess the role of mineralocorticoid excess in essential hypertension.
Main Methods:
- A six-week open-label study involving 25 patients with essential hypertension.
- Administration of spironolactone at 300 mg/day.
- Monitoring of blood urea, potassium, sodium, and bicarbonate levels.
- Assessment of blood pressure response and comparison of electrolyte and electrical properties between responders and non-responders.
Main Results:
- Spironolactone significantly increased blood urea and potassium, while decreasing sodium and bicarbonate.
- Blood pressure normalized in 6 of 25 patients; minimal change was observed in 5 patients.
- No significant differences in electrolyte balance or electrical properties were found between patients who responded and those who did not.
Conclusions:
- High-dose spironolactone impacts electrolyte balance in patients with essential hypertension.
- The drug demonstrated limited effectiveness in normalizing blood pressure in this cohort.
- Mineralocorticoid excess appears to be an infrequent cause of essential hypertension, and spironolactone's mechanism requires further elucidation.
Abstract:
The effect of a six-week course of spironolactone 300 mg/day was examined in 25 unselected patients with essential hypertension. In the blood spironolactone produced a significant rise in urea and potassium concentrations and a fall in sodium and bicarbonate concentrations. In six patients blood pressure was normal at the end of the course, while in five patients there was almost no change. Studies of the effects of spironolactone on various indices usually affected by mineralocorticoids-namely, blood electrolytes, total body potassium, and rectal electrical properties-showed no differences between responding and non-responding patients. Mineralocorticoid excess therefore seems to be rarely responsible for essential hypertension and the influence of spironolactone cannot at present be fully explained.